Should all patients who test positive for HSV‑2 IgG be placed on daily suppressive antiviral therapy?

Should All HSV-2 IgG Positive Patients Receive Daily Suppressive Therapy?

No, not all patients who test positive for HSV-2 IgG should be placed on daily suppressive antiviral therapy. Suppressive therapy should be reserved for specific clinical scenarios rather than universally prescribed based solely on seropositivity.

Clinical Decision Framework

The decision to initiate suppressive therapy depends on three key factors:

1. Frequency and Severity of Clinical Recurrences

Daily suppressive therapy is recommended for patients with frequent or severe recurrences 1. The guidelines specifically define "frequent recurrences" as six or more episodes per year 2, 3, 2, 3.

• Suppressive therapy reduces recurrence frequency by ≥75% 3
• Effective regimens include:
  • Acyclovir 400 mg twice daily
  • Valacyclovir 500 mg twice daily (or 250 mg twice daily, or 1000 mg once daily)
  • Famciclovir 250 mg twice daily 3

Important caveat: The option for suppressive therapy should be discussed with every HSV-2-infected patient 1, but this does not mean all should receive it—only those meeting clinical criteria.

2. Asymptomatic HSV-2 Seropositive Patients

Many HSV-2 seropositive individuals have no history of recognized genital herpes symptoms. For these patients:

• Routine suppressive therapy is NOT recommended for asymptomatic seropositive individuals without recurrent outbreaks
• While suppressive therapy reduces asymptomatic viral shedding by 71-94% 4, 5, the clinical benefit for transmission prevention in real-world settings remains uncertain 3
• The extent to which suppressive therapy prevents HSV transmission is unknown 3

3. Special Populations Requiring Consideration

HIV-Coinfected Patients:

• Suppressive therapy should be considered for the first 6 months after starting antiretroviral therapy (ART), particularly for those with CD4 count <200 cells/μL, to reduce genital ulcer disease risk 6
• Use valacyclovir 500 mg twice daily (or twice-daily regimens of acyclovir or famciclovir) in HIV-infected persons 1
• Important: Suppressive therapy does NOT reduce HIV transmission risk in HIV/HSV-2 coinfected individuals 6

Pregnant Women:

• Suppressive therapy is NOT used routinely during pregnancy 1
• Consider acyclovir in late pregnancy for women with recurrent genital herpes to suppress outbreaks and reduce cesarean delivery need 1
• Acyclovir is the first-choice agent during pregnancy 1

Serodiscordant Couples:

• Daily valacyclovir (500 mg once daily) in the infected partner reduces symptomatic HSV-2 transmission by 75% and overall acquisition by 48% 7
• This represents a specific indication where suppressive therapy may be offered to reduce transmission risk, even without frequent recurrences

Common Pitfalls to Avoid

1. Do not prescribe suppressive therapy based solely on positive HSV-2 IgG serology without assessing clinical recurrence frequency
2. Do not assume suppressive therapy eliminates transmission risk—it reduces but does not eliminate asymptomatic viral shedding 3
3. After 1 year of continuous suppressive therapy, discontinue to reassess recurrence rate, as frequency naturally decreases over time 3
4. No laboratory monitoring is needed for patients on episodic or suppressive therapy unless substantial renal impairment exists 1

Practical Algorithm

For HSV-2 IgG positive patients:

• ≥6 recurrences/year → Offer daily suppressive therapy
• <6 recurrences/year → Offer episodic therapy for outbreaks; discuss suppressive therapy option based on patient preference and psychosocial impact
• Asymptomatic (no recognized outbreaks) → No routine suppressive therapy; counsel on transmission risk and safer sex practices
• Serodiscordant couple → Consider suppressive therapy to reduce transmission
• HIV-coinfected → Consider suppressive therapy for first 6 months after ART initiation if CD4 <200
• Pregnant with recurrent herpes → Consider acyclovir in late pregnancy